MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo
about
Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancerMEK and the inhibitors: from bench to bedside.MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer.Establishment of genetically diverse patient-derived xenografts of colorectal cancer.A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors.BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancerDevelopment and characterization of six new human papillary thyroid carcinoma cell lines.The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing mice.MEK inhibitor PD-0325901 overcomes resistance to CK2 inhibitor CX-4945 and exhibits anti-tumor activity in head and neck cancer.New therapies for dedifferentiated papillary thyroid cancerSrc inhibitors in suppression of papillary thyroid carcinoma growth.Characterization of thyroid cancer cell lines in murine orthotopic and intracardiac metastasis models.p21-Activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model.Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma.Evolving approaches to patients with advanced differentiated thyroid cancerDeciphering KRAS and NRAS mutated clone dynamics in MLL-AF4 paediatric leukaemia by ultra deep sequencing analysis.Detection of thyroid cancer stem cells in papillary thyroid carcinoma.Prospects for MEK inhibitors for treating cancer.Discovering novel pharmacogenomic biomarkers by imputing drug response in cancer patients from large genomics studies.Allosteric modulators of MEK1: drug design and discovery.Synthesis and biological evaluation of RGD-conjugated MEK1/2 kinase inhibitors for integrin-targeted cancer therapy.Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice.Cationic liposomal co-delivery of small interfering RNA and a MEK inhibitor for enhanced anticancer efficacy.Pluripotency markers are differentially induced by MEK inhibition in thyroid and melanoma BRAFV600E cell lines.Adenosine triphosphate prevents serum deprivation-induced apoptosis in human mesenchymal stem cells via activation of the MAPK signaling pathways.The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors.
P2860
Q27324821-C459DDE0-5350-48B1-8748-1A8C1F88ACECQ34036341-87F362FA-ABAD-44D1-B3D7-D4BA4584D3C1Q34584317-0985CCB2-0E7E-4E72-B906-16F7986C3E96Q34704942-E1ADDB4B-5BA7-4208-9CAE-BC950280C763Q34818301-3B8662AB-B09A-48B8-B950-611CCE084A63Q34919430-D21723AC-3C79-482A-AA68-B38B683410F9Q35055107-E6E7BD84-932F-47FA-81DD-C000CEE8E07EQ35067622-23CA655E-1B8E-4F80-A589-CF27763DBF3EQ35197507-341E7AB6-0B6D-4ECA-AA67-52DDF8A0AA81Q35381593-5F778AD1-9C20-4D46-9899-8B8C9A156BE4Q35457965-118D0626-BADB-4B49-BCC1-8C010C24E82FQ35554680-625957EC-935A-4CB6-9E45-AD905C7E5F03Q36405845-041F9CC1-93A3-4D11-862E-8040C26E94BFQ36557486-A308270A-DF32-4970-9A56-1880367ADB8BQ36864736-808EDBEF-C212-4473-914C-CF056AAC72A4Q37306997-2901FE16-0597-4111-A8C7-A86224494859Q37554739-0E10E89B-33D7-42BF-8D45-32D2776AF14EQ38193520-D4C95C55-693A-4E02-9E1B-D9BF4D774BA9Q38605171-740C4B73-308F-4F35-85AD-06801E466EBBQ38817910-6484E2D7-2242-4275-9901-BFDE2E420698Q39063433-41A721D1-FA1E-4002-B139-7D3BC0BAAB43Q39333811-38E217AC-C8F1-4277-A006-0B90011B2F0BQ39481822-AFBA3882-453D-4EA1-99CE-7C3DA7A78160Q41982963-C7608E31-3830-42A4-8CAA-A80CDC75731DQ42194108-2A0C9E30-E985-4DE8-9FF8-37D6493A4EF0Q47786514-7650B287-788E-4349-BF08-A886391A4AC1
P2860
MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
MEK inhibitor PD0325901 signif ...... oma cells in vitro and in vivo
@ast
MEK inhibitor PD0325901 signif ...... oma cells in vitro and in vivo
@en
MEK inhibitor PD0325901 signif ...... oma cells in vitro and in vivo
@nl
type
label
MEK inhibitor PD0325901 signif ...... oma cells in vitro and in vivo
@ast
MEK inhibitor PD0325901 signif ...... oma cells in vitro and in vivo
@en
MEK inhibitor PD0325901 signif ...... oma cells in vitro and in vivo
@nl
prefLabel
MEK inhibitor PD0325901 signif ...... oma cells in vitro and in vivo
@ast
MEK inhibitor PD0325901 signif ...... oma cells in vitro and in vivo
@en
MEK inhibitor PD0325901 signif ...... oma cells in vitro and in vivo
@nl
P2093
P2860
P1476
MEK inhibitor PD0325901 signif ...... oma cells in vitro and in vivo
@en
P2093
Gary L Clayman
Mitchell J Frederick
Stephen Y Lai
Ying C Henderson
Yunyun Chen
P2860
P304
P356
10.1158/1535-7163.MCT-10-0062
P577
2010-06-29T00:00:00Z